MLANA and melanoma: For example, it was recently observed that the heteroclitic 10mer epitope ELAGIGILTV derived from MART-1/Melan-A, which is commonly used in melanoma clinical trials, primes a population of CD8+ T cells that is very poor at cross-recognizing the dominant naturally presented 9mer epitope AAGIGILTV (35, 36).